valsartan has been researched along with Cancer of Nasopharynx in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chien, CY; Lin, YT; Su, YY; Tsai, MH; Wang, HC; Yang, MY | 1 |
| Wang, Q; Wu, G; Zhao, W | 1 |
2 other study(ies) available for valsartan and Cancer of Nasopharynx
| Article | Year |
|---|---|
Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma.
Topics: Angiotensin Receptor Antagonists; Apoptosis; Humans; Losartan; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Retrospective Studies; Signal Transduction; Survival Rate; Treatment Outcome; Valsartan | 2021 |
Valsartan inhibits NPC cell line CNE-2 proliferation and invasion and promotes its sensitivity to radiation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Cobalt Radioisotopes; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gamma Rays; Humans; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Radiation Tolerance; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Tumor Cells, Cultured; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2009 |